Anteris Technologies (AVR)
Develops the investigational DurAVR valve system built on ADAPT tissue.
Something off on this page? Send us feedback.
Develops the investigational DurAVR transcatheter aortic-valve system and related ADAPT tissue platform for severe aortic stenosis. Revenue remains tied to ADAPT tissue products while the main valve business depends on PARADIGM trial execution, manufacturing scale-up, and U.S. and European approvals.
Builds the DurAVR Transcatheter Heart Valve System for aortic stenosis, combining a single-piece ADAPT tissue valve with the ComASUR delivery system. The company also reports ADAPT tissue products and v2vmedtech development work, but its public identity is DurAVR-first.
Operates across Australia and the United States, with principal executive offices in Toowong and a U.S. key location in Eagan. The current issuer is a Delaware parent created through a reorganization of an Australian public-company predecessor and listed on Nasdaq.
Execution centers on the PARADIGM Trial, regulatory submissions for U.S. PMA and European CE Mark approval, and scaling DurAVR-related manufacturing into ISO-qualified clean-room facilities. Capital availability and regulatory clearance shape the path to commercialization because DurAVR remains investigational.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| May 15, 2026 | Barclays | Reiterate | Overweight | $18 |
| Jan 23, 2026 | Lake Street | Target | $15 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $257.4M · Total debt $3.3M · Total assets $272.5M · Shareholders' equity $251.4M
- Revenue
- $1.0M
- Operating income
- −$31.0M
- Net income
- −$29.1M
No dividends on record.
| Institutions131 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 65.82% | 64.15M shares | |
| Insiders8 holders · as of Aug 20, 2026 | 0.47% | 458.8K shares | |
| Strategic holders1 holder · as of Jan 29, 2026 | 16.06% | 15.65M shares | |
| Otherremainder | ≈ 17.65% | 17.20M shares |
97.46M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Medtronic plcStrategic10 percent owner | 16.06% | 15.65M | Form 4filed Jan 29, 2026 ↗ |
L1 Capital Pty LtdInstitution | 7.99% | 7.79M | 13Fas of Mar 31, 2026 |
Nantahala Capital Management, LLCInstitution | 5.68% | 5.53M | 13Fas of Mar 31, 2026 |
Sio Capital Management, LLCInstitution | 5.52% | 5.38M | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 5.02% | 4.89M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 28, 2026 | L1 Capital Pty Ltd | 10 percent owner | −7,800 | $8.83 |
| Aug 11, 2026 | L1 Capital Pty Ltd | 10 percent owner | −375,815 | $9.30 |
| Aug 10, 2026 | L1 Capital Pty Ltd | 10 percent owner | −251,844 | $9.10 |
| Aug 6, 2026 | L1 Capital Pty Ltd | 10 percent owner | −174,721 | $8.10 |
| Aug 5, 2026 | L1 Capital Pty Ltd | 10 percent owner | −14,581 | $8.23 |
- Edwards Lifesciences
Largest direct TAVR and structural-valve benchmark.
- Medtronic
Major Evolut TAVR rival and strategic investor.
- Abbott
Navitor TAVI and broader structural-heart competitor.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Anteris Technologies | $8.67 | +0.81% | $835.2M | — | — | 372.5 | +63.3% |
| Edwards Lifesciences | $90.90 | +0.10% | $52.29B | 52.2 | 28.9 | 8.0 | +13.6% |
| Medtronic | $92.40 | +0.22% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Abbott | $110.50 | +0.04% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Median | 35.5 | 19.0 | 4.1 | +13.6% |